Pathological complete response to trastuzumab and paclitaxel in a patient with inflammatory local recurrence following breast conserving surgery

• Published in: Breast cancer (Tokyo, Japan) Japan), 2005, Vol.12 (3), p.226-230
• Main Authors: Nomura, Masaya, Inoue, Yoshifumi, Fujita, Shigeo, Sakao, Jun, Hirota, Masaki, Souda, Shigeo, Ohshima, Masato
• Format: Article
• Language: English
• Subjects: Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Breast Neoplasms - drug therapy; Breast Neoplasms - surgery; Carcinoma, Ductal, Breast - drug therapy; Carcinoma, Ductal, Breast - surgery; Female; Humans; Inflammation; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local - drug therapy; Paclitaxel - administration & dosage; Remission Induction; Reoperation; Trastuzumab; Treatment Outcome
• ISSN: 1340-6868; 1880-4233
• DOI: 10.2325/jbcs.12.226

We encountered a case of inflammatory local recurrence of breast cancer after breast conserving surgery which attained pathological CR after combination therapy with trastuzumab and paclitaxel. The patient was a 49-year-old premenopausal woman whose left breast cancer(T2N0M0)was treated by breast conserving surgery (Bp+Ax). The pathological diagnosis was scirrhous carcinoma, g, ly1, v0, t2, n0, ER (-), PgR (+) and stage I A. Postoperatively, the residual breast was treated by 50 Gy irradiation followed by hormone therapy(Tamoxifen citrate+LH-RH analog). At 26 months after the surgery, local recurrence developed as inflammatory breast cancer. As the recurrent tumor was confirmed to be HER2-positve (3+ by IHC), combination therapy with trastuzumab and paclitaxel was started. After the 6 courses of pharmacotherapy were completed, she was judged to have clinical CR, and subsequently underwent total breast excision(Bt)and skin grafting. No visible cancer cell was observed in the resected specimens, pathological CR was diagnosed. Postoperatively, the patient is receiving trastuzumab alone every other week, and at present 10 months after the second operation, the patient is in CR status and is visiting the outpatient clinic. No severe side effects (over grade 3) from this therapy have been observed. It is suggested that combination therapy with trastuzumab and paclitaxel for inflammatory local recurrence after breast conserving surgery is a treatment of choice.